Back to Miscellaneous News
Next-Generation Gene Synthesis Company Gen9 Appoints Jennifer A. Camacho as Chief Legal and Business Counsel
Wednesday, April 09, 2014
Gen9, Inc., a pioneer in the development of scalable technologies for synthesizing and assembling DNA, today announced the appointment of Jennifer A. Camacho as Chief Legal and Business Counsel. In this new role, Ms. Camacho will lead the company's intellectual property strategy, regulatory compliance and general legal affairs. As a member of the executive team, she will report to Chief Executive Officer Kevin Munnelly.
"Jennifer is widely regarded as one of the top IP attorneys in the nation and we are honored to welcome her to the Gen9 team," said Munnelly. "This is an exciting time of growth for Gen9, as well as for the synthetic biology industry, and Jennifer's expertise in intellectual property and complex regulatory requirements will be essential as we expand our operations and grow our base of customers in the agbio, chemical engineering and biomedical R&D industries."
Ms. Camacho joins Gen9 from the Boston office of Greenberg Traurig, LLP, where she was a partner focused on intellectual property. In this capacity, she represented clients in synthetic biology, industrial biotechnology, pharmaceuticals, regenerative medicine, protein engineering, chemistry, and biofuels, among others. Prior, Ms. Camacho was with Proskauer Rose LLP, where she was Chief Patent Counsel. Her corporate experience includes vice president of IP at Codon Devices. Camacho is routinely recognized for her leadership and work, particularly in the life sciences and emerging technology sectors. She was named an "IP Star" by Managing Intellectual Property magazine and was awarded the Tech Luminary and Innovation All-Star Award by the Boston Business Journal and Mass High Tech. She is a graduate of the University of Illinois at Urbana-Champaign and received her JD from Boston College Law School.
"The field of synthetic biology represents one of the most exciting areas of intellectual property law and I am looking forward to working with Gen9, our customers and the global community of stakeholders who are committed to ensuring the constructive application of synthesized DNA," said Ms. Camacho.
Gen9 also announced today that it has moved into a new state-of-the-art business office and laboratory facility at Riverside Technology Center, located at 840 Memorial Drive in Cambridge, Mass.
Gen9 has developed unique, next-generation technologies for synthesizing and assembling DNA constructs for use in numerous synthetic biology applications, including antibody, peptide and enzyme engineering; gene and pathway building; and genome construction. Today, Gen9 is manufacturing and shipping double-stranded GeneBits(tm), GeneBytes(tm), and GeneBytes Plus(tm) DNA constructs, or gene fragments from 500 to 10,000 base pairs long. The company's innovative BioFab(R) platform has the capacity to generate tens of thousands of synthetic gene fragments per year in just a few square feet of laboratory space.
More information can be found at www.Gen9Bio.com.
Gen9 is the premier next-generation gene synthesis company focused on high-quality, high-throughput, automated production of DNA constructs. The Gen9 technology allows for the lowest-cost and highest-quality DNA constructs commercially available. Founded by world leaders in synthetic biology, Gen9 aims to ensure the constructive application of synthetic biology in industries ranging from enzyme and chemical production to pharmaceuticals and biofuels. Gen9 is powering the synthetic biology revolution from our headquarters in Cambridge, Mass., and can be found online at www.gen9bio.com.
Gen9, GeneBits, GeneBytes and BioFab are trademarks or registered trademarks of Gen9, Inc. All other brands may be trademarks of their respective holders.
Back to Miscellaneous News